Stem Cell Clinic

CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health…

By adminNovember 12, 2020Stell Cell Research

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders and diseases with an initial focus on neuropathic pain and epilepsy, today announced it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). As part of theNIH Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM, the funding of $670,000 over two years will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain. Orion P. Keifer, Jr. M.D., Ph.D., Vice President, Discovery and Translation at CODA, will serve as the program's principal investigator.

"We are unwavering in our commitment to developing novel chemogenetic therapies for the treatment of neurological disorders and diseases like neuropathic pain for which current treatment options have significant limitations," said Michael Narachi, President and Chief Executive Officer, CODA. "We are honored to receive this grant from NINDS, as this funding will help advance our chemogenetic platform toward human clinical trials where we hope to demonstrate transformative results for patients."

CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach for neuropathic pain by deploying a chemogenetic strategy for treating neuropathic pain sensations at their origin. The Company's innovative treatment aims to modulate specific neuronal circuits where pain arises via adeno-associated virus-mediated delivery of an engineered inhibitory receptor. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule agonist. CODA expects this treatment will produce substantially improved and durable pain relief while potentially avoiding off-target/adverse effects of currently available treatments.

The NINDS SBIR/Small Business Technology Transfer (STTR) program funds small business concerns to conduct innovative neuroscience research and/or development that has both the potential for commercialization and public health benefit.

In addition, CODA was recently selected to collaborate with NIH's National Center for Advancing Translational Science (NCATS), also as part of the NIH HEAL initiative. CODA will partner with the Stem Cell Translation Laboratory led by Ilyas Singec, M.D., Ph.D., in the NCATS Division of Preclinical Innovation (DPI) in developing induced pluripotent stem cell (iPSC)-derived human Ab sensory neurons for the identification and characterization of novel neuropathic pain therapies. The joint NCATS/CODA collaboration will leverage expertise and technologies available at Dr. Singec's lab to jointly develop protocols for generating iPSC-derived A primary sensory neurons, which CODA will then use for the identification and evaluation of inhibitory chemogenetic receptors for the treatment of neuropathic pain. G. Steven Dodson, Ph.D., Vice President of Pharmacology and Early Development at CODA will serve as lead collaborator.

"Ab neurons are a key cell type for the evaluation of our receptor-ligand combinations and their development should advance the translational understanding of how our approach may impact pain states in patients. Through this partnership, CODA will collaborate with and gain access to the scientific capabilities, expertise, state-of-the-art technologies, and resources of the NCATS DPI to develop iPSC-derived human Ab sensory neurons, which will help us progress our neuropathic pain therapies toward the clinic," added Mr. Narachi.

About Neuropathic Pain According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction.

About the CODA Platform CODA's chemogenetic platform aims to reverse the aberrant neuronal activity underlying many neurological disorders. With chemogenetics, dysfunctional neurons are modified using optimized adeno-associated virus (AAV) vectors delivered directly to them by standard-of-care neurosurgical procedures. The AAV vectors encode ligand-gated ion channels (chemogenetic receptors) that are highly responsive to specific proprietary small molecule therapeutics but are otherwise inactive. The activity of these receptors, and thus the aberrant activity of the modified neurons, is controlled in a selective and tunable manner through administration of the small molecule to generate therapeutic benefit with minimal side effects.

About CODA Biotherapeutics CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat neurological disorders and diseases. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA is located in South San Francisco, CA. For more information, please visit http://www.codabiotherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coda-biotherapeutics-receives-grant-from-the-national-institute-of-neurological-disorders-and-stroke-ninds-of-the-national-institutes-of-health-nih-to-help-advance-its-next-generation-gene-therapy-mediated-chemogenetic-platfor-301168028.html

SOURCE CODA Biotherapeutics, Inc.

View original post here:
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health...

Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -…

By adminNovember 12, 2020Induced Pluripotent Stem Cells

This article was originally published here

Stem Cells Transl Med. 2020 Nov 11. doi: 10.1002/sctm.20-0132. Online ahead of print.

ABSTRACT

Critical limb ischemia is a condition in which tissue necrosis occurs due to arterial occlusion, resulting in limb amputation in severe cases. Both endothelial cells (ECs) and vascular smooth muscle cells (SMCs) are needed for the regeneration of peripheral arteries in ischemic tissues. However, it is difficult to isolate and cultivate primary EC and SMC from patients for therapeutic angiogenesis. Induced pluripotent stem cells (iPSCs) are regarded as useful stem cells due to their pluripotent differentiation potential. In this study, we explored the therapeutic efficacy of human iPSC-derived EC and iPSC-derived SMC in peripheral artery disease model. After the induction of mesodermal differentiation of iPSC, CD34+ progenitor cells were isolated by magnetic-activated cell sorting. Cultivation of the CD34+ progenitor cells in endothelial culture medium induced the expression of endothelial markers and phenotypes. Moreover, the CD34+ cells could be differentiated into SMC by cultivation in SMC culture medium. In a murine hindlimb ischemia model, cotransplantation of EC with SMC improved blood perfusion and increased the limb salvage rate in ischemic limbs compared to transplantation of either EC or SMC alone. Moreover, cotransplantation of EC and SMC stimulated angiogenesis and led to the formation of capillaries and arteries/arterioles in vivo. Conditioned medium derived from SMC stimulated the migration, proliferation, and tubulation of EC in vitro, and these effects were recapitulated by exosomes isolated from the SMC-conditioned medium. Together, these results suggest that iPSC-derived SMC enhance the therapeutic efficacy of iPSC-derived EC in peripheral artery disease via an exosome-mediated paracrine mechanism.

PMID:33174379 | DOI:10.1002/sctm.20-0132

The rest is here:
Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -...

Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -…

By adminNovember 12, 2020Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells (iPSCs) Market Overview

The Global Induced Pluripotent Stem Cells (iPSCs) Market is showing positive signs of growth. With the current COVID-19 pandemic scenario, new business opportunities are sprouting in the market. Organizations must explore new markets to expand their business globally and locally. For getting a deeper understanding of the emerging trends, the Global Induced Pluripotent Stem Cells (iPSCs) Market report showcases various factors that drive the economy worldwide. Moreover, the companies will get to know the market landscape for the next decade 2020-2027.

The Global Induced Pluripotent Stem Cells (iPSCs) Market report has been uniquely designed to cater to the needs of the businesses of the 21st century. Going digital is the new normal. Moreover, companies can get to understand their strengths and weaknesses after assessing the market. The next decade is going to be ruled by customer-centric services. To align the business operations, the management team can utilize the actionable recommendations offered at the end of the Global Induced Pluripotent Stem Cells (iPSCs) Market report. Factors that can lift or reduce the business are termed as the external factors that also govern the functioning of the market or industries as a whole.

Before designing the blueprint, every business group can go through the Global Induced Pluripotent Stem Cells (iPSCs) Market report to understand the key business areas. For shaping a new business venture or expanding into a new market, every company must look into the opportunities and threats that are lurking in the current market. To make an efficient business plan, corporations need to understand the market dynamics that will shape the market in the forecast period (2020-2027).

Following key players have been profiled with the help of proven research methodologies:

Induced Pluripotent Stem Cells (iPSCs) Market: Competitive Landscape

To get a head start in a new market, every enterprise needs to understand the competitive landscape and the basic rules that have kept the specific market afloat. The global Induced Pluripotent Stem Cells (iPSCs) Market report unravels the secret ingredients used by competitors to meet the demands of their target audience. For specifically understanding the need to balance the capital invested with profits, organizations must use specific indicators. These indicators will not only help in pointing towards growth but also act as an alert to the upcoming threats in the near future. A proper business plan and approach can guarantee a smooth path ahead for every organization.

If the firms believe in offering a memorable experience to their prospective customers, the Global Induced Pluripotent Stem Cells (iPSCs) Market report is going to be very useful. Facts and figures are churned into this investigative report to share the strengths and weaknesses of the company. With new technologies being introduced every day, many new entrants have started their business in the market. So, to understand their approach towards the market, the Global Induced Pluripotent Stem Cells (iPSCs) Market report has a dedicated section. From the financial aspect to legal, the market report covers all the major things required to study the market and put the business plan in action. Not only this, the competitors added in the report can be altered as per the clients needs and expectations. Furthermore, the companies get a basic outline of moves, in the Global Induced Pluripotent Stem Cells (iPSCs) Market report, that can push the business to emerald heights, both in terms of sales and customer generation for the estimated time frame (2020-2027).

Induced Pluripotent Stem Cells (iPSCs) Market Segmentation:

The Induced Pluripotent Stem Cells (iPSCs) Market has been examined into different global market segments such as type, applications, and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Type:

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Application:

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Induced Pluripotent Stem Cells (iPSCs) Market: Scope of the Report

To properly get a deeper understanding of the Global Induced Pluripotent Stem Cells (iPSCs) Market, this detailed report is the best choice for businesses. To boost the business along with gaining an edge over the competition, every enterprise needs to focus on the pain points of the market (under investigation). Our experienced professionals have collated facts and figures.

This in-depth analysis has revealed many fascinating facts for organizations. For smooth functioning, every business needs to be flexible towards the latest market trends. For this, the framework must be designed to adapt to the trends running at the moment. An end-to-end examination done on the target crowd helped in building the fundamental segment of the investigation, namely the external factors. These have a high tendency to push or pull the industries. Entire industries can either flourish or wipe out due to these uncontrollable factors. Global Induced Pluripotent Stem Cells (iPSCs) market report shows the most affordable options for new as well as established business players to gain market share.

With the highly experienced and motivated team at your service, the team also provides the impact of major factors such as Porters five forces. In the Global Induced Pluripotent Stem Cells (iPSCs) Market, every business runs on the image that is generated digitally in the current decade. Hence, companies need to understand the legal hurdles also. Moreover, with the in-depth study conducted across the various market verticals, it is crystal clear that stakeholders also play a significant role in running the business. Get all the details in the Global Induced Pluripotent Stem Cells (iPSCs) Market report and understand your competitors.

Key questions answered through this analytical market research report include:

What are the latest trends, new patterns and technological advancements in the Induced Pluripotent Stem Cells (iPSCs) Market? Which factors are influencing the Induced Pluripotent Stem Cells (iPSCs) Market over the forecast period? What are the global challenges, threats and risks in the Induced Pluripotent Stem Cells (iPSCs) Market? Which factors are propelling and restraining the Induced Pluripotent Stem Cells (iPSCs) Market? What are the demanding global regions of the Induced Pluripotent Stem Cells (iPSCs) Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

More:
Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -...

Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells – BioSpace

By adminNovember 12, 2020Induced Pluripotent Stem Cells

Proteintechs recent acquisition of nanobody manufacturer, ChromoTek, has made them a leading player in the nanobody space. ChromoTeks high-performing camelid single-chain recombinant reagents, also known as nanobodies, fuel breakthrough research discoveries.

HebeCell holds unique expertise and intellectual property in induced pluripotent stem cells (iPSC) and their lineage specific differentiation, especially toward natural killer (NK) cells. Although NK cells are best known for killing virally infected cells, they also play key roles in detecting and controlling early signs of cancer.

Partnering with Proteintech will give both companies a competitive edge, said Dr. Allen Feng, the Founder and Chief Scientific Officer of HebeCell, Our combined expertise and technologies create a unique and special collaboration that will improve the treatment and care of cancer patients.

Dr. Jason Li, CEO of Proteintech added, Ive known Dr. John Lu, Founder and CEO of HebeCell, for many years and Im glad we have an opportunity to work together on this important project. With HebeCells proprietary NK cells and Proteintechs nanobodies, the two companies can transform the future of cancer therapy.

About Proteintech Group Inc.

Proteintech is a leading manufacturer of antibodies, proteins and immunoassays across research areas. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. After the acquisition of manufacturer, ChromoTek, Proteintech now provides innovative reagents based on camelid antibodies called nanobodies. Proteintech sites are ISO13485 and ISO9001-2015 accredited.

About HebeCell Corporation

HebeCell, founded in 2016, focuses on the fields of Immunotherapy by developing human induced pluripotent stem cell (iPSC)-based off-the-shelf CAR-natural killer (CAR-NK) and other immune cell therapeutics targeting hematological malignancies and solid tumors, as well as autoimmune and infectious diseases. HebeCell has expertise and assets in iPSC specific lineage cell differentiation and state-of-the-art cGMP cell manufacturing facility. Its first-in-class proprietary 3D manufacturing platform for human iPSC-CAR-NK cells is feeder-free and designed specifically for single-use-bioreactor at industrial scale, which allows rapid deploy off-the-shelf CAR-NK cell products for all patients. HebeCells platform technology will accelerate the application of iPSC cells as a viable source of immune cells in the next generation of immunotherapy and will alter the CAR-NK cell therapy field by delivering cost effective allogenic therapeutics worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005786/en/

See the rest here:
Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells - BioSpace

Global Induced Pluripotent Stem Cells Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2026 -…

By adminNovember 12, 2020Induced Pluripotent Stem Cells

There are millions of them around the globe waiting for clutching on to some of the latest vital information circulating across the globe. The up-to-the-minute Induced Pluripotent Stem Cells market report based on the growth and the development of theInduced Pluripotent Stem Cells marketis systematically listed down. The Induced Pluripotent Stem Cells market report comprises statistically verified facts such the unique essence including topological investigations, worldwide market share, government stringent norms, applications, current trends, futuristic plans, market bifurcations, and so on mentioned in a crystal clear pattern.

The statistical plus scientific Induced Pluripotent Stem Cells market report has all the important market aspects penciled down in a layman language format so that the data based on the markets productivity or future strategy can be easily extrapolated from the reports. The Induced Pluripotent Stem Cells market report has the dominant market players Fate Therapeutics, Waisman Biomanufacturing, Bone Therapeutics SA, System Biosciences, Ocata Therapeutics Inc., BrainStorm Cell Therapeutics Inc., CellTherapies P/L, Cellular Dynamics, Lonza, Cellectics, Regeneus Ltd., Stemgent, Iperian, Organogenesis Inc explained in detail.

Sample of global Induced Pluripotent Stem Cells Market Report at::https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003#RequestSample

The essential futuristic segments such as {Adult Sources, Fetal Sources, Others}; {Hematopoietic stem cell transplantation, Tissue repair damage, Autoimmune diseases, As gene therapy vectors.} have also been detailed out in the Induced Pluripotent Stem Cells market report for the clients convenience and more of vital data embracing capability. The forecast trends along with the current market status can better understand the Induced Pluripotent Stem Cells market development on a global basis. The intricate industrial strategies and the supply-demand chain are also discussed in the contextual report.

Key points of the global Induced Pluripotent Stem Cells market

Theoretical analysis of the global Induced Pluripotent Stem Cells market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The Induced Pluripotent Stem Cells market report has the imperative data mentioned in a systematic way only after comprehensive inspection and vigilant referencing. The diagrammatic representations such as a pie chart of the Induced Pluripotent Stem Cells market are also drawn out so as to attract the punters and make it easy for them to comprehend the entire Induced Pluripotent Stem Cells market from in and out. The most eye-catching format of the Induced Pluripotent Stem Cells market report is its market bifurcation based on the product type, application, geography, end-users, and more as per the particular market. The geographical segments Europe, North America, Latin America, Asia Pacific, and Middle East & Africa are further exhaustively mentioned.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003

Questions answered in the report include

1. What is the expected market size by the end of the forecast period? 2. What are the major factors initiating the global Induced Pluripotent Stem Cells market growth? 3. What are the latest developments and trending market strategies that are influencing the growth of the Induced Pluripotent Stem Cells market? 4. What are the key outcomes of the Induced Pluripotent Stem Cells market developments? 5. Who are the key players in the market? 6. What are the opportunities and challenges faced by the key players?

The Induced Pluripotent Stem Cells market report endows the global market dominance, market segmentation, growth factors, and others reported such that the clients can have a total tour of the market without any much off efforts needed.

Key Reasons for Purchasing Global Induced Pluripotent Stem Cells Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

Ask Any Kind of Query Before Purchasing the Report Here:https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003#InquiryForBuying

Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,…

By adminNovember 12, 2020Induced Pluripotent Stem Cells

A New business Strategy report released by DBMR with title Global Stem Cell Manufacturing Market (COVID-19 Version) Study Forecast till 2027. This Market report brings data for the estimated year 2020 and forecasted till 2027 in terms of both, value (US$ MN) and volume (MT).The report also consists of forecast factors, macroeconomic factors, and a market outlook of the market. The study is conducted by applying both top-down and bottom-up approaches and further iterative methods used to validate and size market estimation and trends of the Global Stem Cell Manufacturing Market. This report provides information regarding Stem Cell Manufacturing market size, trends, growth, cost structure, capacity, revenue and forecast 2027.The report explains the moves of top market players and brands that range from developments, product launches, acquisitions, mergers, joint ventures, trending innovation and business policies. Additionally to compliment insights EXIM data, consumption, supply and demand Figures, raw price analysis, market revenue and gross margins.

Stem cell manufacturing is forecasted to grow at CAGR of 6.42% to an anticipated value of USD 18.59 billion by 2027 with factors like rising awareness towards diseases like cancer, degenerative disorders and hematopoietic disorders is driving the growth of the market in the forecast period of 2020-2027.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-manufacturing-market&AB

Stem cell manufacturing has shown an exceptional penetration in North America due to increasing research in stem cell. Increasing research and development activities in biotechnology and pharmaceutical sector is creating opportunity for the stem cell manufacturing market.

The Global Stem Cell Manufacturing Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Manufacturing Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Global Stem Cell Manufacturing Market Segematation By Product (Stem Cell Line, Instruments, Culture Media, Consumables), Application (Research Applications, Clinical Applications, Cell and Tissue Banking), End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others)

List of TOP KEY PLAYERS in Stem Cell Manufacturing Market Report are

Thermo Fisher Scientific Merck KGaA BD JCR Pharmaceuticals Co., Ltd Organogenesis Inc Osiris Vericel Corporation AbbVie Inc AM-Pharma B.V ANTEROGEN.CO.,LTD Astellas Pharma Inc Bristol-Myers Squibb Company FUJIFILM Cellular Dynamics, Inc RHEACELL GmbH & Co. KG Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Ltd ViaCyte,Inc VistaGen Therapeutics Inc GlaxoSmithKline plc ..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-manufacturing-market&AB

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell Manufacturing industry. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell Manufacturing manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The Global Stem Cell Manufacturing Market Trends, development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product, the stem cell manufacturing market is segmented into stem cell lines, instruments, culture media and consumables. Stem cell lines are further segmented into induced pluripotent stem cells, embryonic stem cells, multipotent adult progenitor stem cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells. Instrument is further segmented into bioreactors and incubators, cell sorters and other instruments.

On the basis of application, the stem cell manufacturing market is segmented into research applications, clinical applications and cell and tissue banking. Research applications are further segmented into drug discovery and development and life science research. Clinical applications are further segmented into allogenic stem cell and autologous stem cell therapy.

On the basis of end users, the stem cell manufacturing market is segmented into hospitals and surgical centers, pharmaceutical and biotechnology companies, research institutes and academic institutes, community healthcare, cell banks and tissue banks and others.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Key Insights in the report:

Historical and current market size and projection up to 2025

Market trends impacting the growth of the global taste modulators market

Analyze and forecast the taste modulators market on the basis of, application and type.

Trends of key regional and country-level markets for processes, derivative, and application Company profiling of key players which includes business operations, product and services, geographic presence, recent developments and key financial analysis

For More Information or Query or Customization Before Buying, Visit @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market&AB

Opportunities in the market

To describe and forecast the market, in terms of value, for various segments, by region North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW)

The key findings and recommendations highlight crucial progressive industry trends in the Stem Cell manufacturing Market, thereby allowing players to develop effective long term strategies

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across Europe.

To get a comprehensive overview of the Stem Cell manufacturing market.

With tables and figures helping analyses worldwide Global Stem Cell Manufacturing Market Forecast this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. There are 15 Chapters to display the Stem Cell Manufacturing market.

Chapter 1, About Executive Summary to describe Definition, Specifications and Classification of Stem Cell Manufacturing market, By Product Type, by application, by end users and regions.

Chapter 2, objective of the study.

Chapter 3, to display Research methodology and techniques.

Chapter 4 and 5, to show the Stem Cell Manufacturing Market Analysis, segmentation analysis, characteristics;

Chapter 6 and 7, to show Five forces (bargaining Power of buyers/suppliers), Threats to new entrants and market condition;

Chapter 8 and 9, to show analysis by regional segmentation[North America, Europe, Asia-Pacific etc ], comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain Analysis

Chapter 10, to identify major decision framework accumulated through Industry experts and strategic decision makers;

Chapter 11 and 12, Stem Cell Manufacturing Market Trend Analysis, Drivers, Challenges by consumer behavior, Marketing Channels

Chapter 13 and 14, about vendor landscape (classification and Market Ranking)

Chapter 15, deals with Stem Cell Manufacturing Market sales channel, distributors, Research Findings and Conclusion, appendix and data source.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Originally posted here:
Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,...

Induced Pluripotent Stem Cells Market Comprehensive Insights, Growth, Forecast and Covid-19 Impact by 2026 | Medipost Co. Ltd., Ocata Therapeutics…

By adminNovember 12, 2020Induced Pluripotent Stem Cells

Global Induced Pluripotent Stem Cells market report offers a precise outline of the market that includes many aspects of market product definition, market segmentation, analysis, key developments, and existing vendors state of the business. These Induced Pluripotent Stem Cells industry documents include key players and geographical markets that have adopted vital methodologies for business developments and growth. The consumer trust in precise and proper Induced Pluripotent Stem Cells information structures that is employed for analysis of the business Report 2020 has the aim to deliver a complete analysis of the Induced Pluripotent Stem Cells market. The report could assist you in coming up with worthy growth methods and additionally aware and indurate challenges.

Perpetually increasing in the market, often rise in customers demands are the notable factors of growing and developing the business. Taking thought of each segments Induced Pluripotent Stem Cells market report is deliberate by creating each analysis of the market conditions worldwide. Examine the restraining Induced Pluripotent Stem Cells segments affecting the business in the coming future has been into consideration.

Get a Sample Copy of the Report at https://www.futuristicreports.com/request-sample/52069

Impact of COVID-19 on Induced Pluripotent Stem Cells Market

The report also contains the effect of the ongoing worldwide pandemic, i.e., COVID-19, on the Induced Pluripotent Stem Cells Market and what the future holds for it. It offers an analysis of the impacts of the epidemic on the international market. The epidemic has immediately interrupted the requirement and supply series. The report also assesses the economic effect on firms and monetary markets. Futuristic Reports has accumulated advice from several delegates of this business and has engaged from the secondary and primary research to extend the customers with strategies and data to combat industry struggles throughout and after the COVID-19 pandemic.

Global Induced Pluripotent Stem Cells Market: Competitive Landscape

(Medipost Co. Ltd., Ocata Therapeutics Inc., Lonza, Regeneus Ltd., Fate Therapeutics, Organogenesis Inc., Waisman Biomanufacturing, Cellectics, Stemgent, CellTherapies P/L, Cellular Dynamics, BrainStorm Cell Therapeutics Inc., Viacyte, Axiogenesis, System Biosciences, Bone Therapeutics SA, Reprocell, Iperian)

Segment by Type, the Induced Pluripotent Stem Cells market is segmented into

Adult Sources Fetal Sources Others

Segment by Application, the Induced Pluripotent Stem Cells market is segmented into

Hematopoietic stem cell transplantation Tissue repair damage Autoimmune diseases As gene therapy vectors.

To Understand How Covid-19 Impact Is Covered in This Report With additional Discount: https://www.futuristicreports.com/check-discount/52069

This report also splits the market by region:

United States Canada Mexico Brazil APAC China Japan Korea

Key Questions Answered in The Report:

Market Report includes major TOC points 1 Study Coverage 1.1 Induced Pluripotent Stem Cells Product Introduction 1.2 Market Segments 1.3 Key Induced Pluripotent Stem Cells Manufacturers Covered: Ranking by Revenue 1.4 Market by Type 1.4.1 Global Induced Pluripotent Stem Cells Market Size Growth Rate by Type 1.4.2 Measuring Smart Plug 1.4.3 Regular Smart Plug 1.4.4 Remote Control Smart Plug 1.4.5 Other 1.5 Market by Application 1.5.1 Global Induced Pluripotent Stem Cells Market Size Growth Rate by Application 1.5.2 Home 1.5.3 Commercial 1.6 Study Objectives 1.7 Years Considered

2 Executive Summary 2.1 Global Induced Pluripotent Stem Cells Market Size, Estimates and Forecasts 2.1.1 Global Induced Pluripotent Stem Cells Revenue 2016-2026 2.1.2 Global Induced Pluripotent Stem Cells Sales 2016-2026 2.2 Global Induced Pluripotent Stem Cells, Market Size by Producing Regions: 2016 VS 2020 VS 2026 2.3 Induced Pluripotent Stem Cells Historical Market Size by Region (2016-2020) 2.3.1 Global Induced Pluripotent Stem Cells Retrospective Market Scenario in Sales by Region: 2016-2020 2.3.2 Global Induced Pluripotent Stem Cells Retrospective Market Scenario in Revenue by Region: 2016-2020 2.4 Induced Pluripotent Stem Cells Market Estimates and Projections by Region (2021-2026) 2.4.1 Global Induced Pluripotent Stem Cells Sales Forecast by Region (2021-2026) 2.4.2 Global Induced Pluripotent Stem Cells Revenue Forecast by Region (2021-2026)

3 Global Induced Pluripotent Stem Cells Competitor Landscape by Players 3.1 Global Top Induced Pluripotent Stem Cells Sales by Manufacturers 3.1.1 Global Induced Pluripotent Stem Cells Sales by Manufacturers (2016-2020) 3.1.2 Global Induced Pluripotent Stem Cells Sales Market Share by Manufacturers (2016-2020) 3.2 Global Induced Pluripotent Stem Cells Manufacturers by Revenue 3.2.1 Global Induced Pluripotent Stem Cells Revenue by Manufacturers (2016-2020) 3.2.2 Global Induced Pluripotent Stem Cells Revenue Share by Manufacturers (2016-2020) 3.2.3 Global Induced Pluripotent Stem Cells Market Concentration Ratio (CR5 and HHI) (2016-2020) 3.2.4 Global Top 10 and Top 5 Companies by Induced Pluripotent Stem Cells Revenue in 2019 3.2.5 Global Induced Pluripotent Stem Cells Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Global Induced Pluripotent Stem Cells Price by Manufacturers 3.4 Global Induced Pluripotent Stem Cells Manufacturing Base Distribution, Product Types 3.4.1 Induced Pluripotent Stem Cells Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Induced Pluripotent Stem Cells Product Type 3.4.3 Date of International Manufacturers Enter into Induced Pluripotent Stem Cells Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2016-2026) 4.1 Global Induced Pluripotent Stem Cells Market Size by Type (2016-2020) 4.1.1 Global Induced Pluripotent Stem Cells Sales by Type (2016-2020) 4.1.2 Global Induced Pluripotent Stem Cells Revenue by Type (2016-2020) 4.1.3 Induced Pluripotent Stem Cells Average Selling Price (ASP) by Type (2016-2026) 4.2 Global Induced Pluripotent Stem Cells Market Size Forecast by Type (2021-2026) 4.2.1 Global Induced Pluripotent Stem Cells Sales Forecast by Type (2021-2026) 4.2.2 Global Induced Pluripotent Stem Cells Revenue Forecast by Type (2021-2026) 4.2.3 Induced Pluripotent Stem Cells Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Induced Pluripotent Stem Cells Market Share by Price Tier (2016-2020): Low-End, Mid-Range, and High-End

5 Market Size by Application (2016-2026) 5.1 Global Induced Pluripotent Stem Cells Market Size by Application (2016-2020) 5.1.1 Global Induced Pluripotent Stem Cells Sales by Application (2016-2020) 5.1.2 Global Induced Pluripotent Stem Cells Revenue by Application (2016-2020) 5.1.3 Induced Pluripotent Stem Cells Price by Application (2016-2020) 5.2 Induced Pluripotent Stem Cells Market Size Forecast by Application (2021-2026) 5.2.1 Global Induced Pluripotent Stem Cells Sales Forecast by Application (2021-2026) 5.2.2 Global Induced Pluripotent Stem Cells Revenue Forecast by Application (2021-2026) 5.2.3 Global Induced Pluripotent Stem Cells Price Forecast by Application (2021-2026)

..Continued

Inquire or Share Your Questions If Any before the Purchasing This Report https://www.futuristicreports.com/send-an-enquiry/52069

Our Other Reports:

Pre-Shave Market Qualitative, Quantitative Research on Leading Players and Covid-19 Impact by 2026 | Beiersdorf AG, Godrej Group, Johnson & Johnson and Others

Silicon Plate Market by Type, Product Analysis, Applications and Covid-19 Impact by 2026 | Shin-Etsu Chemical, GlobalWafers, Ferrotec and Others

Car Holder Market Detailed Analysis, Regional Outlook and Covid-19 Impact by 2026 | Philips, X-power, VOSSON and Others

Bathtub Spouts Market In-Depth Study: Trends, Analysis and Covid-19 Impact by 2026 | MKH, California Faucets, Palazzani.EU and Others

Futuristic Reports

Name: Mark Rivera Tel: +1-408-520-9037 Email: [emailprotected]

See original here:
Induced Pluripotent Stem Cells Market Comprehensive Insights, Growth, Forecast and Covid-19 Impact by 2026 | Medipost Co. Ltd., Ocata Therapeutics...

Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to…

By adminNovember 12, 2020Stem Cell Medicine

Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205

About Regenerative Medicine Advanced Therapy (RMAT) DesignationEstablished under the 21st Century Cures Act, the RMAT designation was established to facilitate development and expedite review of cell therapies and regenerative medicines intended to treat serious or life-threatening diseases or conditions. Advantages include the benefits of the FDA's Fast Track and Breakthrough Therapy Designation programs, such as early interactions with the FDA to discuss potential surrogate or intermediate endpoints to support accelerated approval.

About HDT-AHCT High-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT) is considered a standard-of-care therapy for patients with aggressive systemic Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).Although efficacious and considered a potential cure, HDT-AHCT is associated with severe regimen-related toxicities (SRRT) that increase patient morbidity and risk for mortality, especially in the aging population. Effective prevention of SRRT may lead to more patients being eligible for a potential cure through HDT and stem cell transplantation.

About SRRT Consequences of Diffuse Injury to the Organ Vascular NichesThe human body is capable of renewing, healing and restoring organs.For example, the human oral-GI tract renews its lining every 3 to 7 days. Both the organ renewal and healing processes are dependent on organ stem cell vascular niches made up of stem cells, endothelial cells (cells that line blood vessels) and supportive cells.When tissues are injured, the vascular niche endothelial cells direct the stem cells, via angiocrine factor expression, to repair and restore the damaged tissue. This restorative capacity is most active during childhood and youth but starts to diminish with increasing age.HDT provided to eradicate cancer cells also cause diffuse, collateral damage to vascular niches of multiple healthy organs. In particular, the organs with the highest cell turnover (ones with most active vascular niches) are severely affected.Specifically, the oral-GI tract, dependent on constant renewal of its mucosal lining, starts to break down upon vascular niche injury.The mucosal breakdown can cause severe nausea, vomiting and diarrhea. In addition, the bacteria in the gut may escape into the circulation, resulting in patients becoming ill with endotoxemia, bacteremia or potentially lethal sepsis.HDT-related vascular niche damage can also occur in other organs resulting in severe or life-threatening complications involving the lung, heart, kidney, or the liver.Collectively, these complications are known as severe regimen-related toxicities or SRRT.SRRT can occur as frequently as 50% in lymphoma HDT-AHCT patients, with increased rate and severity in older patients.

About AB205AB-205 is a first-in-class engineered cell therapy consisting of proprietary 'universal' E-CEL (human engineered cord endothelial) cells.The AB-205 cells are intravenously administered after the completion of HDT on the same day as when the patient's own (autologous) blood stem cells are infused. AB-205 acts promptly to repair injured vascular niches of organs damaged by HDT.By repairing the vascular niches, AB-205 restores the natural process of tissue renewal, vital for organs such as oral-GI tract and the bone marrow. Successful and prompt organ restoration can prevent or reduce SRRT, an outcome that is beneficial to quality of life and cost reductive to the healthcare system.

About CIRMThe California Institute for Regenerative Medicine (CIRM) was established in November, 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure provided $3 billion in funding for California universities and research institutions.With over 300 active stem cell programs in their portfolio, CIRM is the world's largest institution dedicated to stem cell research. For more information, visit http://www.cirm.ca.gov.

About Angiocrine Bioscience Inc.Angiocrine Bioscience is a clinical-stage biotechnology company developing a new and unique approach to treating serious medical conditions associated with the loss of the natural healing and regenerative capacity of the body.Based on its novel and proprietary E-CEL platform, Angiocrine is developing multiple therapies to address unmet medical needs in hematologic, musculoskeletal, gastrointestinal, soft-tissue, and degenerative/aging-related diseases.A Phase 3 registration trial is being planned for the intravenous formulation of AB-205 for the prevention of severe complications in lymphoma patients undergoing curative HDT-AHCT.This AB-205 indication is covered by the Orphan Drug Designation recently granted by the US FDA.In addition, Angiocrine is conducting clinical trials of local AB-205 injections for the treatment of: (1) rotator cuff tear in conjunction with arthroscopic repair; and, (2) non-healing perianal fistulas in post-radiation cancer patients.

For additional information, please contact:

Angiocrine Bioscience, Inc. John R. Jaskowiak (877) 784-8496 [emailprotected]

SOURCE Angiocrine Bioscience, Inc.

Link:
Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to...

Regenerative Medicine Market with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast till 2026 – Illadel Graff Supply

By adminNovember 12, 2020Stem Cell Medicine

The latest report on Regenerative Medicine market collated by Market Study Report, LLC, delivers facts and numbers regarding the market size, geographical landscape and profit forecast of the Regenerative Medicine market. In addition, the report focuses on major obstacles and the latest growth plans adopted by leading companies in this business.

Request a sample Report of Regenerative Medicine Market at: https://www.marketstudyreport.com/request-a-sample/1695290?utm_source=illadelink&utm_medium=RV

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

Enquiry about Regenerative Medicine market report before Buying at: https://www.marketstudyreport.com/enquiry-before-buying/1695290?utm_source=illadelink&utm_medium=RV

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Purchase full report of Regenerative Medicine market at: https://www.marketstudyreport.com/securecheckout/paymenta/1695290?utm_source=illadelink&utm_medium=RV?msfpaycode=sumsf

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

Regenerative Medicine Market share byMajor regions included:

United States North America Asia Pacific Europe Middle East & Africa

Table of Contents

1. Overview and Scope 1.1. Research goal & scope 1.2. Research assumptions 1.3. Research Methodology 1.3.1. Primary data sources 1.3.2. Secondary data sources 1.4. Key take-away 1.5. Stakeholders 2. Executive Summary 2.1. Market Definition 2.2. Market Segmentation 3. Regenerative Medicine Market Insights 3.1. Regenerative Medicine Industry snapshot 3.2. Regenerative Medicine Ecosystem analysis 3.3. Regenerative Medicine Market Dynamics 3.3.1. Regenerative Medicine Market Forces 3.3.1.1. Regenerative Medicine Market Driver Analysis 3.3.1.2. Regenerative Medicine Market Restraint/Challenges analysis 3.3.1.3. Regenerative Medicine Market Opportunity Analysis 3.4. Industry analysis Porters five force 3.4.1. Bargaining power of supplier 3.4.2. Bargaining power of buyer 3.4.3. Threat of substitute 3.4.4. Threat of new entrant 3.4.5. Degree of competition 3.5. Regenerative Medicine Market PEST Analysis 3.6. Regenerative Medicine Market Value Chain Analysis 3.7. Regenerative Medicine Industry Trends 3.8. Competitive Ranking Analysis 4. Regenerative Medicine Market Size and Forecast by Therapy Type, 2018-2026 4.1. Key Findings 4.2. Tissue engineering 4.3. Cell Therapy 4.4. Immunotherapy 4.5. Gene Therapy 5. Regenerative Medicine Market Size and Forecast by Product Type, 2018-2026 5.1. Key Findings 5.2. Acellular Products 5.3. Cellular Products

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Market Study Report LLC

Phone: 1-302-273-0910

US Toll Free: 1-866-764-2150

Email:sales@marketstudyreport.com

Read the original post:
Regenerative Medicine Market with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast till 2026 - Illadel Graff Supply

Leading Human Immunology and Infectious Disease Experts to Join UM School of Medicines Institute of Human Virology – Newswise

By adminNovember 12, 2020Stem Cell Medicine

Newswise Baltimore, MD, November 12, 2020 Robert C. Gallo, MD, the Homer & Martha Gudelsky Distinguished Professor in Medicine at the University of Maryland School of Medicine (UMSOM) and Co-Founder & Director of the UMSOMs Institute of Human Virology (IHV), announced today that a team of leading scientists in human immunology, virology and stem cell biology, led by Lishan Su, PhD joined IHV on October 1 with academic appointments in the UMSOM Department of Pharmacology. As part of the Maryland E-Nnovation Initiative Fund (MEIF) to recruit top research faculty and a donation to IHV from the Charles Gordon Estate, Dr. Su has been named the Charles Gordon Smith Endowed Professor for HIV Research. Dr. Su will also head IHVs Division of Virology, Pathogenesis and Cancer.

The team will include a 12-person Laboratory of Viral Pathogenesis and Immunotherapy with two faculty appointments as well as major public and private sector research funding.

Dr. Gallo made the announcement in conjunction with University of Maryland School of Medicine Dean E. Albert Reece, MD, PhD, MBA and Margaret M. McCarthy PhD, James & Carolyn Frenkil Deans Professor, Chair of the Department of Pharmacology.

Dr. Su is one of the most successful active basic researchers in America, said Dr. Gallo, who is also Co-Founder and Chairman of the International Scientific Leadership Board of the Global Virus Network. His research is groundbreaking, and we are so pleased to have him join IHV and lead our Division of Infectious Agents and Cancer, which under his sound leadership, will flourish.

Dr. McCarthy added:Dr. Sus continuing ground-breaking work in HIV and Hepatitis B will be a huge asset to the Department of Pharmacology. I look forward to working with him on advances that could open the door to new therapeutics.

Dr. Su was a faculty member in the Lineberger Comprehensive Cancer Center and Professor in the Department of Microbiology & Immunology at University of North Carolina-Chapel Hill since 1996. He received his BS degree in Microbiology from Shandong University, his PhD degree in Virology from Harvard University, and did his post-doctoral training in Stem Cell Biology & Immunology at Stanford University. He worked as a senior research scientist at SyStemix/Sandoz (Novartis), focusing on HIV-1 pathogenesis and stem cell-based gene therapy in humanized mice and in patients.

I am excited to continue and expand my research programs at the Institute of Human Virology (IHV), said Dr. Su. I have long been impressed by the Baltimore-DC area's research centers with great basic and clinical research programs. IHV, co-founded and directed by Dr. Robert Gallo, is one of the first research institutes in the U.S. to integrate basic science, population studies and clinical trials to understanding and treating human virus-induced diseases. The Department of Pharmacology, headed by Dr. Margaret McCarthy, in the University of Maryland School of Medicine, has been outstanding in developing novel therapeutics including breast cancer drugs. I look forward to working with my new colleagues at IHV and the Department of Pharmacology, and across the University of Maryland School of Medicine, to expand and translate my research programs to treating human inflammatory diseases including virus infection and cancer.

Dr. Su has extensive research experience in human immunology, virology and stem cell biology. Dr. Su made important contributions to several areas of human immunology and infectious diseases, particularly in studying human immuno-pathology of chronic virus infections. His lab at UNC-Chapel Hill published important findings in identifying novel virological and immunological mechanisms of HIV-1 pathogenesis. Furthermore, his lab established humanized mouse models with both human immune and human liver cells that support HCV or HBV infection, human immune responses and human liver fibrosis. In recent years, Dr. Sus group discovered, and focused on, the pDC-interferon axis in the immuno-pathogenesis and therapy of chronic HIV & HBV infections. The group also started investigation of the pDC-IFN axis in tumor microenvironments and in cancer immune therapy.

Im so pleased to welcome Dr. Su to our faculty. His work advances the mission of the School of Medicine, which is to provide important new knowledge in the area of immunology and chronic disease to discover new approaches for treatments, said Dean Reece, who is also University Executive Vice President for Medical Affairs and the John Z. and Akiko K. Bowers Distinguished Professor. Dr. Sus stellar research capabilities will provide vital opportunities for collaboration across our Institutes and Departments.

About the Institute of Human Virology

Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably, HIV the virus that causes AIDS. For more information,www.ihv.organd follow us on Twitter @IHVmaryland.

About the University of Maryland School of Medicine

The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Marylands Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global vision, with research and treatment facilities in more than 30 countries around the world. For more information, visitwww.medschool.umaryland.edu.

View post:
Leading Human Immunology and Infectious Disease Experts to Join UM School of Medicines Institute of Human Virology - Newswise